Nuwellis Inc vs YieldMax NVDA Option Income Strategy ETF — how do they compare? Nuwellis Inc trades at $2.94 (market cap $1.09M), while YieldMax NVDA Option Income Strategy ETF trades at $12.59. Which is the better fit depends on your goals.
| NUWE | NVDY | |
|---|---|---|
Market Cap | $1.09M | — |
Sector | Technology | Income / Options Overlay |
52-Week High | $527.46 | $17.96 |
52-Week Low | $2.80 | $12.03 |
Enterprise Value | -$722.58K | — |
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $3.00, up 5.26% over 24 hours, following a recent 35:1 reverse stock split effective June 26, 2026. The stock shows a bearish technical signal with all moving averages indicating sell. Fundamentally, the company reported a net loss of $17.52M in 2025, with negative profit margins, though revenue grew to $8.27M. Recent news highlights expansion in pediatric care and a $6M public offering closed in June 2026.
Outlook remains challenging due to persistent losses and high cash burn, but strategic initiatives in pediatric cardiorenal care and new patents offer growth potential. Key risks include negative ROE, reliance on financing, and competitive pressures. Analyst consensus is split evenly between Buy and Hold, reflecting cautious optimism amid financial headwinds.
NVDY (YieldMax NVDA Option Income Strategy ETF) trades at $12.41, showing modest daily gains of 0.4%. The ETF employs a covered call strategy on NVIDIA shares, generating weekly distributions but capping upside potential. Technical indicators signal bearish momentum with moving averages and ADX pointing downward, while oscillators remain neutral. Recent distributions have ranged from $0.10 to $0.21 per share, providing income-focused investors with regular cash flow.
The outlook remains challenging as the covered call strategy sacrifices NVIDIA's explosive growth potential for income generation. Key risks include opportunity cost from missed upside, fund management fees, and dependence on NVIDIA's volatility. While attractive for income seekers, growth-oriented investors may prefer direct NVIDIA exposure given the significant performance trade-off.
Trailing returns across standard periods
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →